Retrospective analysis of Claudin 18.2 expression in 64 patients with advanced gastrointestinal peritoneal disease: a potential therapeutic target for high-grade appendiceal mucinous carcinoma [0.03%]
胃肠道腹膜疾病患者Claudin 18.2表达的回顾性分析：高级别阑尾黏液性癌潜在治疗靶点的一项研究
Colman T Clarke,Ailin C Rogers,Darren Cowzer et al.
Colman T Clarke et al.
Aims: Specific to normal gastric epithelium, Claudin 18.2 (CLDN18.2) is a tight junction protein. CLDN18.2 immunohistochemistry is a companion diagnostic used to identify oesophageal and gastric adenocarcinoma patients el...
Serum versus lithium-heparin plasma for lipid testing: matrix-related bias and calculated LDL-C classification [0.03%]
血脂检测中血清与锂盐肝素抗凝血浆的基质相关偏倚及LDL-C分类差异的研究
Nejd Kouched,Lobna Jmal,Khedija Zaouche et al.
Nejd Kouched et al.
Aims: To assess whether serum and lithium-heparin plasma can be used interchangeably for routine lipid testing and whether matrix-related bias affects calculated low-density lipoprotein (LDL)-cholesterol (LDL-C) classific...
Beyond root cause analysis: a practical systems engineering approach to incident investigation in histopathology [0.03%]
超越根本原因分析：实用于组织病理学事件调查的系统工程方法
Omar E Rakha,Emad A Rakha
Omar E Rakha
Patient safety and diagnostic quality are central to modern histopathology practice. Current incident investigation approaches often rely on root cause analysis; however, its routine use as a universal method is insufficient to address the ...
Developing a national proficiency testing programme for biospecimens: the Thailand Biobank Consortium experience [0.03%]
泰国生物样本库联盟的国家级生物样本能力检测计划的发展经验
Piyavat Apisampinvong,Chawanit Wongkasa,Thanastha Thanomchard et al.
Piyavat Apisampinvong et al.
Aims: To address the absence of nationally accessible proficiency testing (PT) for biospecimens in Thailand, we developed and evaluated a pilot PT programme consisting of four schemes covering DNA extraction, quantificati...
Artificial Intelligence in Digital Pathology for Prostate Cancer Detection: FDA Clearance and Real-World Implementation [0.03%]
前列腺癌检测的数字病理人工智能：FDA批准与实际应用
Quinn Rainer,Yue Sun,Monika Vyas et al.
Quinn Rainer et al.
Artificial intelligence (AI) has emerged as a promising adjunct in surgical pathology, particularly in the diagnosis of prostate cancer, where variability in interpretation or missed cancer foci can significantly affect patient management. ...
Promise and pragmatism of AI in global-scale digital pathology: pan-cancer approaches for clinical practice [0.03%]
人工智能在数字病理学中的承诺与务实：临床实践的泛癌方法
Sarah E Coupland,Arvind Rao,Danny Jonigk et al.
Sarah E Coupland et al.
Artificial intelligence (AI) tools for digital pathology have crossed the threshold from pilot project to clinical deployment, with regulatory approvals, commercial products and prospective trials now accumulating across multiple tumour typ...
Development and internal validation of a multifactorial risk model for predicting disease-free survival in oral squamous cell carcinoma [0.03%]
用于预测口腔鳞状细胞癌无病生存率的多因素风险模型的开发和内部验证
Anand Ramanathan,Wan Maria Nabillah Ghani,Sarah Sabrina Zakaria et al.
Anand Ramanathan et al.
Aims: To develop and validate a multifactorial risk model for predicting disease-free survival (DFS) in oral squamous cell carcinoma (OSCC) by integrating pathological features with systemic and tissue-based inflammatory ...
HER2-low as a unique subgroup in breast cancer: insights from neoadjuvant chemotherapy response and survival analysis [0.03%]
乳腺癌中HER2低表达亚型的特征：新辅助化疗疗效及生存分析揭示
Zhengyang Dong,Si Wu,Jiaxian Miao et al.
Zhengyang Dong et al.
Aims: Traditional breast cancer treatment relies on binary human epidermal growth factor receptor 2 (HER2) classification, while HER2-low breast cancer represents an intermediate subgroup. Given the efficacy of novel anti...
Rebekah Beattie,Joanne Motte,Neil R Borley et al.
Rebekah Beattie et al.